Zeo Energy Corp. Reports Second Quarter 2025 Financial Results

Zeo Energy Corp. Reports Second Quarter 2025 Financial Results GlobeNewswire August 13, 2025 NEW PORT RICHEY, Fla., Aug. 13, 2025 (GLOBE NEWSWIRE) — Zeo Energy Corp. (Nasdaq: ZEO) (“Zeo,” “Zeo Energy,” or the “Company”), a Florida-based provider of residential solar and energy efficiency solutions, today reported financial results for the second quarter and six months […]

Neuronascent Announces Progress for Lead Candidate NNI-362: Publication of Phase 1a Clinical Trial Results and FDA Grants Waiver of Fee for Canine Cognitive Disorder 2025 Submissions

Neuronascent Announces Progress for Lead Candidate NNI-362: Publication of Phase 1a Clinical Trial Results and FDA Grants Waiver of Fee for Canine Cognitive Disorder 2025 Submissions GlobeNewswire August 13, 2025 BALTIMORE., Aug. 13, 2025 (GLOBE NEWSWIRE) — Neuronascent Inc., a privately-held neuron regeneration therapeutics company, today announced that the Phase 1a trial in aged human

Canadian Credit Market Shows Signs of Recovery as New Mortgages Rise 51% Year-Over-Year

Canadian Credit Market Shows Signs of Recovery as New Mortgages Rise 51% Year-Over-Year GlobeNewswire August 13, 2025 Key findings from TransUnion report: Inflation continues to be a key driver of the growth in consumer balances over the last three years, with average non-mortgage balances rising 10% since 2022 Home affordability remains a challenge as average

European Wax Center, Inc. Reports Second Quarter Fiscal Year 2025 Results

European Wax Center, Inc. Reports Second Quarter Fiscal Year 2025 Results Updates fiscal 2025 outlook GlobeNewswire August 13, 2025 Second Quarter Fiscal 2025 versus 2024 1,059 total centers in 44 states was flat System-wide sales of $257.6 million decreased 1.0% Total revenue of $55.9 million decreased 6.6% Same-store sales increased 0.3% GAAP net income of

AirSculpt Technologies Announces Participation in Sidoti Micro Cap Conference

AirSculpt Technologies Announces Participation in Sidoti Micro Cap Conference GlobeNewswire August 13, 2025 MIAMI BEACH, Fla., Aug. 13, 2025 (GLOBE NEWSWIRE) — AirSculpt Technologies, Inc. (NASDAQ: AIRS) (“AirSculpt” or the “Company”), a national provider of premium body contouring procedures, today announced that the Company will participate in the Sidoti Micro Cap Conference being held virtually

PureSoftware, a Happiest Minds Company, Secures Two Honors at IBSi Digital Banking Awards 2025 for Arttha’s Excellence in Digital Lending and Wallet Innovation

PureSoftware, a fully owned subsidiary of Happiest Minds, is proud to announce that its flagship digital banking platform, Arttha, has won two top honors at the prestigious IBSi Digital Banking Awards 2025. Arttha was recognized as the Functional Area Winner in Digital Wallet for G-Money Financial Services, a wholly-owned subsidiary of GCB Bank (one of

ADAMA Continues Upward Trend in ESG Performance, Ranked in the Top Quartile of the Industry in Latest EcoVadis Rating

Marks fifth consecutive year of improvement, ranking in the top 23% of the Manufacture of Pesticides and Other Agrochemical Products industry – including top 14% for environment and top 5% for ethics ADAMA Ltd. (SZSE: 000553), a leading global crop protection company, has improved its position in the EcoVadis Sustainability Rating. The company is now

PlanHub Earns Spot on Inc. 5000 for Fifth Consecutive Year, Defying Growth Odds Among America’s Fastest-Growing Companies

PlanHub,the leading cloud-based preconstruction platform, has once again been named to the Inc. 5000 list of the fastest-growing private companies in America, ranking No. 1786 for 2025. This marks PlanHub's fifth consecutive appearance on the prestigious list-a milestone that underscores the company's rare ability to sustain rapid growth over time, even as year-over-year revenue increases

Telitacicept Meets Primary Endpoint in Phase III Trial for Primary Sjögren’s Syndrome in China

On August 13th,Remegen (688331.SH/09995.HK) announced that its global first-in-class BLyS (BAFF)/APRIL dual-target fusion protein drug, Telitacicept, met the primary endpoint in its Phase III clinical trial for the treatment of primary Sjögren's syndrome (pSS) in China, as per the pre-specified study protocol. The company will promptly submit a Biologics License Application (BLA) to the Center

Scroll to Top